CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of ...

Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a ...

Helius Medical Technologies (NASDAQ:HSDT) on Wednesday has priced its public offering, that includes 2,768,600 Class A common ...

June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem ...

Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirementNEWTOWN, ...

June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...

Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health ...